Status:
NOT_YET_RECRUITING
Long-term Follow-up of the TAM-01 Study
Lead Sponsor:
Ente Ospedaliero Ospedali Galliera
Conditions:
Breast Cancer Invasive
Eligibility:
FEMALE
18+ years
Brief Summary
Low-dose tamoxifen (5 mg/day for three years, BabyTam) has emerged as a safer and effective alternative to the standard regimen (20 mg/day), reducing breast cancer recurrence with fewer adverse events...
Detailed Description
Low-dose tamoxifen (5 mg/day for three years) has emerged as a safer alternative to standard-dose tamoxifen (20 mg/day), effectively reducing the risk of breast cancer recurrence while minimizing adve...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Women previously enrolled in the TAM-01 trial (EudraCT number: 2007-007740-10).
- Written informed consent.
- Exclusion criteria:
- None.
Exclusion
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2035
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06982313
Start Date
October 1 2025
End Date
February 1 2035
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
E. O. Ospedali Galliera
Genoa, Italy